Report / Paper metadata
Probiotic supplementation increases fecal TLR4 agonists without improving disease activity in juvenile idiopathic arthritis: a randomized placebo-controlled trial.
A placebo-controlled trial in 44 children with juvenile idiopathic arthritis did not find an improved clinical response with VSL#3 added to standard therapy. A change in a stool immune-signalling measure was not the same as an improvement in arthritis.
Who took part?
The PERMAJI trial enrolled 44 children with oligoarticular or rheumatoid-factor-negative polyarticular juvenile idiopathic arthritis. The children were randomly assigned to VSL#3 or placebo for three months while continuing standard therapy. The study was multicentre, double-blind and placebo-controlled.
What was the main clinical measure?
The main endpoint was the proportion achieving an ACR Pedi 30 response at three months. The researchers also collected stool and blood samples at baseline and at the three-month visit to examine microbial composition, immune agonist activity, intestinal permeability and circulating cytokines.
Did arthritis response improve?
The abstract reports ACR Pedi 30 response in 47% of the probiotic group and 63% of the placebo group, with p = 0.33. That analysis did not show a benefit. A conservative analysis of missing data gave lower response rates for VSL#3: 36% versus 68%, with p = 0.03. The missing-data assumptions therefore matter to the interpretation.
What changed in the laboratory measures?
The probiotic increased measured stool activity of Toll-like receptor 4 agonists. The abstract did not report changes in microbial diversity, intestinal permeability or circulating cytokines. A laboratory change should not be treated as evidence of symptom relief when the clinical endpoint did not improve.
What remains uncertain?
The small trial addresses a specific probiotic preparation in specific arthritis groups over three months. It does not establish the effects of every probiotic or longer-term treatment. This page summarizes the abstract rather than independently reviewing the full paper and is not advice to start, stop or change a child's treatment.
- Journal
- Gut microbes
- Kind
- Paper metadata
- Identifier
- PMID 42720258